Chonluten: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 7 sources cited
Overview
Chonluten is a bioregulatory tripeptide (Glu-Asp-Gly) developed at the Khavinson Institute that targets bronchial mucosa and gastrointestinal epithelium. Published work is limited to a human monocyte cell-line study, in which it lowered inflammatory cytokine release, and a gastric ulcer model. Effects on mucosal barrier function or secretory immunity have not been published, and no human trial was found. Its dual-tissue targeting makes it particularly relevant for aging individuals experiencing concurrent decline in both respiratory and GI mucosal function.
Mechanism of Action
Chonluten is proposed to modulate gene expression in mucosal tissue of the respiratory and gastrointestinal tracts. In a gastric ulcer model the tripeptide Glu-Asp-Gly (studied under the code T-34) normalized the expression of genes for antioxidant and anti-inflammatory proteins; its developers name c-Fos, HSP70, SOD, COX-2 and TNF-α. In human THP-1 monocyte/macrophage cells it reduced TNF and IL-6 release after exposure to bacterial lipopolysaccharide. Effects on secretory IgA, mucins, tight junction proteins or trefoil factors have not been published. Through such effects Chonluten is proposed to help maintain the barrier function that naturally degrades with aging. Fewer respiratory infections, better mucociliary clearance and improved intestinal barrier integrity have not been shown in published studies.
Chonluten Benefits: What the Research Shows
- Reduced TNF and IL-6 release, and less adhesion to activated endothelial cells, in human THP-1 monocyte/macrophage cultures exposed to bacterial lipopolysaccharide (2022 cell study).
- Normalized expression of genes for antioxidant and anti-inflammatory proteins in a gastric ulcer model in a Khavinson Institute study, where the peptide is called T-34.
- Computer docking predicts that the tripeptide can be carried into cells by LAT and PEPT transporters. Binding to gene promoter sequences in pulmonary or intestinal epithelium has not been tested in a published study.
- A long-term study in elderly people reported a 2.0–2.4-fold lower incidence of acute respiratory disease, but it tested Thymalin and Epithalamin, not Chonluten.
- Part of the Khavinson bioregulatory peptide family. The clinical experience this group has published concerns other preparations (Thymalin, Thymogen, Vilon, Epithalamin, Prostatilen, Cortexin, Retinalamin); no human safety data for Chonluten were found.
Chonluten Dosage
- Standard dose: 10 mg subcutaneous injection daily.
- Typical cycle: 10–20 days.
- Repeat every 3–6 months, ideally before respiratory infection season.
- Can be combined with Bronchogen for enhanced respiratory support (Chonluten covers both respiratory and GI mucosa, while Bronchogen is bronchial-specific).
- Oral capsule formulations available at higher doses for those preferring non-injectable administration.
- No food timing restrictions.
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Chonluten Side Effects & Safety
Known Side Effects
- Injection site reactions — mild and uncommon.
- No published human study has reported on adverse events with Chonluten.
- GI effects have not been studied in humans.
- Immune overstimulation has not been assessed in people; in a human monocyte cell line the peptide lowered TNF and IL-6 release after an inflammatory stimulus.
- Short cycle length limits exposure.
Safety Profile
Chonluten has no published human safety study. The decades of clinical use in elderly populations cited for Khavinson bioregulators concern other preparations, such as Thymalin and Epithalamin. The tripeptide is expected to be rapidly metabolized, but its pharmacokinetics and systemic effects have not been measured in people. Contraindications are not established; hypersensitivity and pregnancy/breastfeeding are precautionary exclusions. Drug interactions have not been studied, including with respiratory medications (bronchodilators, inhaled corticosteroids) and GI medications (PPIs, H2 blockers).
What to Expect
Days 1–10: No immediate perceptible effects. Epigenetic modulation of mucosal epithelial gene expression is initiating. Days 11–20: Molecular changes are establishing. Subtle improvements in respiratory comfort or digestive ease may begin for some users. Weeks 3–12 (post-cycle): Suppliers and users describe improved breathing comfort, fewer upper respiratory infections and better digestive tolerance. These reports are anecdotal; no published human study of Chonluten has measured them or any change in the mucosal barrier. Months 3–6: Effects maintain throughout the inter-cycle period. Repeat cycles sustain and build upon the benefits cumulatively.
Common Stacks
Bronchogen
Bronchogen provides additional bronchial-specific bioregulatory support, complementing Chonluten's broader mucosal coverage for comprehensive respiratory health.
Crystagen
Crystagen supports systemic immune function (T-cell maturation), complementing Chonluten's mucosal immune support (secretory IgA) for layered immune defense.
BPC-157
BPC-157's gut mucosal healing, tight junction restoration, and anti-inflammatory effects complement Chonluten's epigenetic mucosal support for comprehensive GI health.
Storage & Handling
Store lyophilized powder refrigerated at 36–46°F (2–8°C). After reconstitution, refrigerate and use within 20 days. Oral capsules: room temperature, cool and dry.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Avolio F, Martinotti S, Khavinson VK, et al. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. Int J Mol Sci. 2022.
- Khavinson VKh, Lin'kova NS, Dudkov AV, et al. Peptidergic regulation of expression of genes encoding antioxidant and anti-inflammatory proteins. Bull Exp Biol Med. 2012.
- Khavinson V, Linkova N, Kozhevnikova E, et al. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. Int J Mol Sci. 2022.
- Khavinson V, Linkova N, Dyatlova A, et al. Peptides: Prospects for Use in the Treatment of COVID-19. Molecules. 2020.
- Khavinson VK, Linkova NS, Rudskoy AI, et al. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules. 2023.
- Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results. Adv Gerontol. 2013.
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003.
Related Peptides
Track Chonluten in Your Protocol
Log your Chonluten doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free